+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 1Year - 6Years
All Genders
ID07046364

Study of Remimazolam Added to Sevoflurane Anesthesia to Reduce Emergence Delirium in Children Aged 1 to 6 Undergoing Neurosurgery

Led by Peking University First Hospital · Updated on 2025-07-01

248

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Emergence delirium is a common problem in children undergoing neurosurgery. Researchers are studying whether adding remimazolam to sevoflurane anesthesia can reduce the risk of this complication in pediatric patients aged 1 to 6 years. This trial is designed to explore the effects of remimazolam when used alongside standard anesthesia during elective neurosurgical procedures. Participants receive either remimazolam or a placebo during surgery. The remimazolam group is given a loading dose of 0.3 mgkg at anesthesia induction followed by a continuous infusion of 1 mgkghour until 10 minutes before the surgery ends. Both groups use sevoflurane to maintain anesthesia depth within a specific range. This study is randomized and quadruple-blinded to compare outcomes accurately. Children will be monitored for emergence delirium at 10, 20, and 30 minutes after arrival in the post-anesthesia care unit or before discharge. Additional assessments include postoperative delirium, pain levels, sleep quality up to one month after surgery, and behavioral changes after surgery. These evaluations help researchers understand the impact of remimazolam on recovery and safety. The study is expected to continue until 2027.

CONDITIONS

Brief Title

Remimazolam and Emergence Delirium in Pediatrics

Research Team

D

Dong-liang Mu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here